Related Experiment Videos
Clodronate in myelofibrosis: a case report
Paul Froom1, Irit Elmalah, Andrei Braester
1Institute of Hematology, Lady Davis Carmel Hospital, Haifa, Israel.
The American Journal of the Medical Sciences
|February 28, 2002
Summary
Oral bisphosphonate therapy, specifically clodronate, shows promise for treating agnogenic myeloid metaplasia (AMM). This treatment led to reduced bone marrow fibrosis and normalized blood counts in a patient with AMM, making them transfusion-independent.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Agnogenic myeloid metaplasia (AMM) is a myeloproliferative disorder characterized by bone marrow fibrosis and extramedullary hematopoiesis.
- Patients with AMM often develop pancytopenia, necessitating frequent blood transfusions.
- Conventional therapies like androgen and interferon have shown limited efficacy and potential adverse effects.
Observation:
- A 59-year-old male patient with documented AMM and pancytopenia required regular blood transfusions.
- Previous treatments with androgen therapy and interferon were ineffective and led to complications.
- The patient was subsequently treated with oral clodronate at a daily dose of 30 mg/kg.
Findings:
- Clodronate treatment resulted in a significant reduction in bone marrow fibrosis.
- Gradual normalization of blood counts was observed over an 8-month treatment period.
- The patient achieved transfusion independence, remaining so for over 33 months post-treatment.
Implications:
- Oral bisphosphonate therapy, exemplified by clodronate, may represent a viable therapeutic option for AMM.
- This approach could potentially mitigate bone marrow fibrosis and improve hematological parameters in AMM patients.
- Further investigation into bisphosphonate efficacy in AMM is warranted based on this case report.